Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Jennifer R. Brown, Filippo Utro et al.|Blood Advances|2022Cited by 79
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samplesJasneet Kaur Khalsa, Jennifer R. Brown, Justin Cha et al.|Blood|2023Cited by 26
Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumorsRisa Burr, Daniel A. Haber, Karsen Seeger et al.|Nature Cancer|2024Cited by 21